Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 3,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

NCT00006373
View directory record Official record
Conditions
Lymphoma
Interventions
etoposide, ifosfamide, topotecan hydrochloride, autologous bone marrow transplantation, Mesna
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 31, 2026, 12:34 AM EDT
Active, not recruiting Not applicable Interventional

The Inspiring Action to Prevent Diabetes Intervention

NCT06001801
View directory record Official record
Conditions
PreDiabetes
Interventions
Diabetes Prevention Program, INSPIRA
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 31, 2026, 12:34 AM EDT
Terminated Phase 2 Interventional Results available

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

NCT00276744
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 2 Interventional Results available

SMART Use of Medication for the Treatment of Adolescent Severe Obesity

NCT04007393
View directory record Official record
Conditions
Adolescent Obesity
Interventions
Lifestyle Modification Therapy (LSMT), Phentermine Pill, Topiramate Pill, Placebo
Behavioral · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Not applicable Interventional

Self-Monitoring Shopping Intervention

NCT04020302
View directory record Official record
Conditions
Intellectual Disability, Down Syndrome
Interventions
Self-monitoring shopping intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hillsborough, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 1 Interventional

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

NCT01713972
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dabrafenib, pazopanib hydrochloride, Correlative studies
Drug · Other
Lead sponsor
Manisha Shah
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 31, 2026, 12:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

NCT04331067
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab, Tumor biopsy, Bone marrow, Blood draw
Drug · Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

NCT01142232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide plus Melphalan during autologous stem cell transplantation, Lenalidomide maintenance
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 31, 2026, 12:34 AM EDT
Withdrawn Phase 2 Interventional

Fulvestrant + Neratinib In Breast Cancer

NCT04901299
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions
NERATINIB, FULVESTRANT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 1 Interventional

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

NCT05396833
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
Tuvusertib, Lartesertib, Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Santa Rosa, California • Miami, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 12:34 AM EDT
Completed No phase listed Observational

Genetic Study of Patients and Families With a History of Colorectal Cancer

NCT00003648
View directory record Official record
Conditions
Colorectal Cancer
Interventions
DNA stability analysis, gene rearrangement analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
11
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Not applicable Interventional Results available

Pilot of Lifestyle and Asthma Intervention

NCT03291808
View directory record Official record
Conditions
Asthma
Interventions
Weight loss intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Tucson, Arizona • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 2 Interventional

Actuate 1901: 9-ING-41 in Myelofibrosis

NCT04218071
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib, 9-ING-41
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Augusta, Georgia • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 2 Interventional Results available

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

NCT01399047
View directory record Official record
Conditions
Juvenile Neuronal Ceroid Lipofuscinosis
Interventions
Mycophenolate mofetil, Liquid Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
6 Years to 25 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 12:34 AM EDT
Recruiting Phase 3 Interventional

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264
View directory record Official record
Conditions
Secondary Immune Deficiency
Interventions
IgPro20
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 31, 2026, 12:34 AM EDT
Terminated No phase listed Observational

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

NCT00899093
View directory record Official record
Conditions
Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Mixed Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Ovarian Neoplasm, Malignant Ovarian Serous Tumor, Malignant Ovarian Transitional Cell Tumor, Ovarian Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
131
States / cities
Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 99 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 31, 2026, 12:34 AM EDT
Active, not recruiting Phase 4 Interventional

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933
View directory record Official record
Conditions
ALK Positive Malignancies
Interventions
ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
5
States / cities
Fayetteville, Arkansas • Loma Linda, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 4 Interventional Results available

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

NCT01289847
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Hyper-IgM Syndrome, Wiskott-Aldrich Syndrome
Interventions
Gammaplex
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
2 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 31, 2026, 12:34 AM EDT
Terminated Phase 1 Interventional

A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients

NCT01984255
View directory record Official record
Conditions
Melanoma
Interventions
Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV, Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 31, 2026, 12:34 AM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

NCT00300885
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development and Testing of a Just-in-Time Adaptive Smart Phone Intervention to Reduce Drinking Among Homeless Adults

NCT03746808
View directory record Official record
Conditions
Alcohol Use Disorder, Treatment, Homelessness
Interventions
EMA + App/Treatment Messages
Behavioral
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
Not listed
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Not applicable Interventional

The Use of Voice-Based AI in 988 Crisis Counseling

NCT06299384
View directory record Official record
Conditions
Suicide, Suicide and Self-harm
Interventions
LyssnCrisis
Other
Lead sponsor
Lyssn.io, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 12:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

NCT02028884
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo, Baseline Treatment
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 74 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 31, 2026, 12:34 AM EDT